COMPANY

Nielsen BioSciences

HQ: San Diego, CA source · nielsenbio.com ↗

Nielsen BioSciences, Inc. is a biopharmaceutical company focused on developing and commercializing biological products with applications in cell-mediated immune responses. From company website Source · checked 2026-10-19

In addition to SPHERUSOL® (Coccidioides immitis Spherule-Derived Skin Test Antigen) used in patients with Valley Fever, Nielsen BioSciences markets CANDIN® (Candida albicans Skin Test Antigen to Assess Cellular Hypersensitivity). From company website Source · 2026-10-12

Sources for this description (1)

Nielsen BioSciences, Inc. is a biopharmaceutical company focused on developing and commercializing biological products with applications in cell-mediated immune responses.
- “Nielsen BioSciences , Inc. is a privately-held, San Diego-based biopharmaceutical company focused on developing and commercializing biological products with wide-ranging applications in cell-mediated immune responses.” https://nielsenbio.com/about-us/ (2026-10-19)

Keywords: Warts Common Warts (Verruca Vulgaris) Human Papilloma Virus Cutaneous Leishmaniasis Coccidioidomycosis Spherule-derived coccidioidin

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Oct 23, 2025 Partnership Partnership / licensing: upfront not published; deal value up to $36M (kept separate from upfront), announced Oct 23, 2025. Source: company's own press page. source ↗
Jan 22, 2025 Trial start Phase 3: Candin for the Treatment of Common Warts source ↗
2015-03 Trial start Phase 2: Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) source ↗
2012-09 Trial start Phase 2: Candin Safety & Efficacy Study for the Treatment of Warts source ↗
2008-08 Trial start Phase 2: Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen source ↗
2005-05 Trial start Phase 3: A Multi-center Study of Spherule-Derived Coccidioidin source ↗

Funding

Last 2 years.

Oct 23, 2025 Partnership / licensing: upfront not published; deal value up to $36M (kept separate from upfront), announced Oct 23, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT05889845	Candin for the Treatment of Common Warts	Phase 3	Completed	Jan 22, 2025	Aug 27, 2025 (actual)
NCT01757392	Candin Safety & Efficacy Study for the Treatment of Warts	Phase 2	Completed	2012-09	2014-12 (actual)
NCT02393417	Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)	Phase 2	Completed	2015-03	2018-01 (actual)
NCT00633009	Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen	Phase 2	Completed	2008-08	2009-09 (actual)
NCT00690092	A Multi-center Study of Spherule-Derived Coccidioidin	Phase 3	Completed	2005-05	2007-09 (actual)